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http://dx.doi.org/10.1016/j.jfma.201Background/Purpose: Evidence on the prevention of radiation dermatitis is lacking. The aim of
this study was to investigate the effect of 3M Cavilon No Sting Barrier Film and topical corti-
costeroids on irradiated skin.
Methods: Thirty-nine postoperative breast cancer patients were randomized into three groups
for intraindividual comparison (skin to be irradiated was divided into 2 parts): (1) 3M No Sting
Barrier Film versus no treatment; (2) corticosteroid versus no treatment; and (3) corticosteroid
versus 3M No Sting Barrier Film. The primary end points monitored were the time to first occur-
rence of grade 1 pruritus, pain score of 3 and grade 2 radiation dermatitis. The secondary end
points studied were the incidence of grade 3 radiation dermatitis and total pain scores. Data
analysis was done using the SPSS software version 10.
Results: Skin given the 3M barrier film experienced a later occurrence of pruritus compared to
both corticosteroids and untreated, although this was statistically insignificant. Corticosteroids
delayed the time to occurrence of grade 2 dermatitis compared to both untreated skin and 3M
barrier film, (mean day of onsetZ corticosteroid: 52 vs. untreated: 43, pZ 0.092; corticoste-
roid: 53.4 vs. 3M barrier film: 44.5, pZ 0.002, t test). Skin given corticosteroids had the lowest
incidence of grade 3 dermatitis among all three conditions, although the differences were sta-
tistically insignificant. No statistically significant differences were noted in total pain scores.ave no conflicts of interest relevant to this article.
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408 S.-Z. Shaw et al.Conclusion: The 3M barrier film may be helpful against dermatitis associated pruritus. Cortico-
steroids may delay the time of onset of severe skin reactions and also reduce the incidence of
severe radiation dermatitis.
Copyright ª 2013, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.Table 1 Common Terminology Criteria for Adverse Events
v3.0 (CTCAE).
Grade Criteria
Dermatitis associated with radiation
1 Faint erythema or dry desquamation
2 Moderate to brisk erythema; a patchy moist
desquamation, mostly confined to skin folds and
creases; moderate edema
3 Moist desquamation other than skin folds and
creases; bleeding induced by minor trauma or
abrasion
4 Skin necrosis or ulceration of full thickness dermis;
spontaneous bleeding from involved site
5 Death
Pruritus/itching
1 Mild or localized
2 Intense or widespread
3 Intense or widespread and interfering with ADLIntroduction
The human epidermis is a relatively radiosensitive organ; it
goes through a series of physical changes as the radiation
dose accumulates over time. A skin reaction is commonly
observed when treatment is delivered to the head and neck
region, breast, post-modified radical mastectomy chest
wall, axilla, groin area or the perineum. These physical
reactions caused by radiation may result in much discom-
fort that affects the general well being of a patient. If se-
vere, the treatment course may even be interrupted.
Several studies have been conducted to find ways of
preventing and managing radiation skin reactions. Prod-
ucts, either medicated or non-medicated, in the form of
lotion, cream, ointment, barrier film or dressing etc, were
used in the trials; however, there was lack of strong evi-
dence and consensus on the issue regarding what to use for
radiation protection and management. One particular
reason was that, as pointed out by Maurene McQuestion and
other reviewers, it is difficult to make comparisons across
studies due to methodological weaknesses, such as small
sample sizes, a wide variety of terms describing reactions,
a variety of measuring tools and different outcomes across
studies.1,2 Furthermore, according to Kumar’s review, only
seven out of 29 articles (studies from 1980 to 2008)
demonstrated statistically significant results for the man-
agement of acute skin toxicity.3 The Cancer Care Ontario’s
Supportive Care Guideline Group, the Belgium nursing
group and researchers such as Kumar in Australia, and
Lavery in the UK, all agreed and recommended gentle skin
washing using either water alone, or with mild soap, for the
prevention of radiation skin reactions. However, they also
concluded that there is insufficient evidence to support or
refute specific oral or topical agents for the prevention and
management of radiation dermatitis, because there were
too many inconsistencies among the trial results.4e6
Breast cancer patients constitute the majority treated in
our radiation department. During the course of radio-
therapy, many patients suffered from dermatitis > grade 2
according to the NCI Common Terminology Criteria for
Adverse Events version 3.0 (Table 1). When moist desqua-
mation occurred, patients often experiences pain and burns
that may last for weeks after treatment. Some skin
breakdown was accompanied by exudates and crusting,
requiring dressing, medication and special wound care, and
this usually caused anxiety, limited activity and inconve-
nience in clothing other than pain and discomfort. This
urged us to find some evidence for protection against
radiation-induced irritation and dermatitis. We think it is
equally as important to minimize the patient’s suffering
during radiation treatment, as to achieve cancer control.
This study thus focused on breast cancer patients,
comparing two products and untreated skin. These prod-
ucts contain two distinctive properties: (1) Mometasonefuroate cream containing 0.1% topical corticosteroid (Elo-
met), which contains chemical antiinflammatory effects;
and (2) 3M Cavilon No-Sting Barrier Film, which is a non-
medicated product that acts as a physical barrier on the
skin against friction and contamination. Elomet was
routinely used in our department once a patient experi-
enced skin itches and pain, but was not advised in the area
of epidermal breakdown or wet desquamation, due to its
adverse effects on wound healing.7 Bostrom et al reported
that the use of mometasone furoate reduces the incidence
of grade IV skin reactions when compared to an emollient
(35% vs. 60%).8 3M Cavilon No-Sting Barrier Film was intro-
duced to our department later. The Australian group, Gra-
ham et al, used 3M Cavilon No-Sting Barrier Film and found
that it reduces the duration and frequency of radiation-
induced moist desquamation and the pruritus score as
compared to sorbolene cream.9
Materials and methods
The IRB committee in our hospital approved this clinical
study, and a total of 39 patients were recruited from
November 2008 to December 2010. All participants signed
inform consent to this study. Each patient was allocated to
one of the three treatment combinations by simple
randomization: (1) 3M barrier film versus no treatment; (2)
Elomet versus no treatment; and (3) Elomet versus 3M
barrier film. Then, each patient’s chest wall, or remaining
breast after breast conserving surgery, was divided into two
skin regions perpendicular to the scar (Fig. 1). On either
side, we applied 3M barrier film, Elomet or left it as un-
treated; therefore, each patient had two skin regions used
Figure 1 Each patient’s chest wall or remaining breast after breast conserving surgery is divided into two skin regions
perpendicular to the scar for different applications.
Protection against radiation dermatitis 409for intraindividual comparison. Each division might have
included axilla, breastesternum junction and lower breast
skin fold in patients receiving breast conserving surgery.
The purpose of this internal control method was intended
to exclude variables, such as previous chemotherapy, in-
dividual sensitivity, or co-morbidities.
Standard radiation fractionation (2 Gy per fraction, five
fractions per week) was used in each patient. Each patient
underwent computed tomography for treatment planning.
A total of 50 Gy was delivered using tangential field to the
remaining breast or chest wall. Wedge filters, bolus and
subfields were applied when necessary, to obtain a uniform
dose distribution. Then, a dose of 10 Gy boost to the tumor
bed and scar region was delivered using electrons. For pa-
tients with more advanced disease, such as lymph node
involvement or chest wall recurrence, regional lymph nodes
(axillary, supraclavicle and internal mammary chain) were
also irradiated. The skin reaction in the supraclavicular or
neck region was not taken into account in this study.
Both Elomet and 3M barrier film were applied to the
allocated skin region every other day, excluding weekends,
during the radiation treatment period, mostly by the same
hospital staff. Skin reactions on the breast or chest wall
were observed, and photographed. Patient assessed itching
and pain scores were recorded weekly, from the beginning
of irradiation, until 4 weeks after completion of treatment
by the same staff. The severity of dermatitis and pruritus
was graded according to NCI Common Terminology Criteria
for Adverse Events version 3.0 (Table 1). Pain score was
graded on a scale of 1 to 10. The day of onset of each event
was given a date from the first day of radiation treatment
for each category. If generalized wet desquamation
occurred, the application of both products was stopped.
Ointment containing an antibiotic was prescribed during
the irradiation, or silver sulfadiazine cream was prescribed
if radiation treatment was completed.
The primary end points monitored were the time to first
occurrence of grade 1 pruritus, a pain score of 3 and grade 2
dermatitis. The secondary end points were the incidences of
grade3acutedermatitis andtotalpainscores recorded ineach
different application (Elomet (mometasone furoate cream),
Schering-Plough; East- Java, Indonesia, 3Mbarrier film (3Mno-sting Cavilon Barrier Film, 3M Health Care; Minnesota, USA) or
untreated). Data analysis was done using the SPSS software
version 10. Pair t test was performed to compare the times to
first occurrence of Grade 1 pruritus, pain score of 3 and Grade
2 dermatitis between any two applications in all three groups.
For the incidences of Grade 3 dermatitis which occurred in
each skin condition, a Chi-square test was performed to
compare the differences. As for total pain score comparison,
we took the sum of the pain scores recorded each week for
each patient from week 1 to 10 and tested the differences
using Wilcoxon signed-rank test. In statistical testing, a two-
sided p value0.05 was considered statistically significant.Results
Thirty-nine patients entered the study; 13 patients were in
the 3M barrier film versus no treatment group, nine were in
the Elomet versus no treatment group, and 17 were in
Elomet versus 3M barrier film. These patients ranged from
30 to 76 years old; mean age Z 51 years. There were 17
patients who had previously received modified radical
mastectomy, 18 had received breast conservation treat-
ment, and four had post-modified radical mastectomy chest
wall recurrence and received tumor excision.
In the group using 3M barrier film and Elomet applica-
tion, we found that skin using 3M barrier film experienced a
later occurrence of Grade 1 pruritus than the use of Elomet
(3M: day 32.4 from first treatment day vs. Elomet: day
28.4). However, this was not statistically significant;
p Z 0.072. In the 3M barrier film versus the untreated
group, it appeared that the application of 3M barrier film
may also delay the occurrence of pruritus in patients (3M:
day 32.5 vs. untreated: day 29.4), but again, the p value
was insignificant; p Z 0.079. In the Elomet versus the un-
treated group, no difference was shown (Elomet: day 26.4
vs. untreated: day 26.8, pZ 0.413). Fig. 2 shows the mean
pruritus score in each application by week of radiotherapy.
Comparing the differences of time to first occurrence of
pain score of 3 in all three groups, we found no significance
differences in all three applications (p Z 0.451 comparing
3M barrier film and Elomet, p Z 0.527 comparing Elomet
410 S.-Z. Shaw et al.with untreated, and p Z 0.618 comparing 3M barrier film
with untreated).
Looking at the time to first occurrence of grade 2
dermatitis, the group Elomet versus 3M barrier film, showed
that by applying Elomet, dermatitis occurred later than the
use of 3M barrier film (Elomet: day 53.4 vs. 3M barrier film:
day 44.5). This difference reached statistical significance;
p Z 0.002. In the group of Elomet versus the untreated
group, Elomet also appeared to delay the time onset of
Grade 2 dermatitis compared to untreated skin, but it
showed no statistical significance; p Z 0.092 (Elomet: day
52 vs. untreated: day 43). Figs. 3 and 4 show skin reactions
of unequal severity in these two groups. In the 3M barrier
film group versus the untreated group, there were similar
results between the two (3M barrier film: day 44.2 vs. un-
treated: day 46.6, p Z 0.196). The summary and compar-
ison regarding the time to first occurrence of these adverse
events is shown in Table 2.
No Grade 4 acute radiation dermatitis was observed in
any of the three different applications. The overall in-
cidences of acute skin reaction of Grade 3 dermatitis irre-
spective of grouping were: (1) 3M barrier film: 10 out of 30
(33%); (2) Elomet: four out of 26 (15%); and (3) untreated:
five out of 22 (23%). However, using the Chi-square test to
compare these results showed that it was statistically
insignificant; p Z 0.289. As for the total pain score recor-
ded with application of 3M barrier film, Elomet and un-
treated skin, no statistically significant difference was
reached in any group using the Wilcoxon sign-rank test. By
comparing 3M barrier film with no treatment, the p value
was 0.759. By comparing Elomet with no treatment, the p
value was 0.786. By comparing Elomet with 3M barrier film,
the p value was 0.369.Discussion
Radiation induced skin reactions is a continuous process; as
the radiation dose accumulates, the severity increases. It0
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Figure 2 Weekly mean patient-assessinvolves (1) disruption of the balance between the normal
production of cells at the basal layer and the destruction or
death of cells at the skin surface; (2) a cascading inflam-
matory response triggered by injured cells, with release of
histamines, serotonin and other proinflammatory mole-
cules; and (3) vascular response.1,10 It has been docu-
mented that 87% of people suffer a moderate to severe
reaction.11 Generally, erythyma may occur after 2e3 weeks
of radiation, as a result of capillary dilatation in the dermis
accompanied by edema, because of increased vascularity
and obstruction.12,13 As the accumulative dose reaches
20 Gy, decreased ability of the basal layer cells to replace
surface layers and decreased functioning of the sweat gland
and sebaceous gland, result in dryness, pruritus, or flaking
of the skin, also known as dry desquamation.14 At a dose of
30e40 Gy, extracapillary cell damage occurs with increased
capillary blood, so we observe hyperemia and edema. Moist
desquamation may occur at doses of 45e60 Gy where the
dermis is exposed. The treatment field is moist, tender and
red, with oozing of serous fluid, or it may be accompanied
by exudates and crusting.12 Ulcer formation, hemorrhage,
and necrosis are less common but represent more severe
damage.1,15 These skin changes are identified and graded
by severity (Table 1).
Factors affecting the severity of skin reaction include
both patient-related factors and treatment-related factors.
Patient-related risk factors include: concurrent chemo-
therapy, immunotherapy, or target therapy, associated
medical condition or co-morbidities such as diabetes or
renal failure, old age, compromised nutritional status,
smoking chronic sun exposure, and other environmental
conditions.16,17 Treatment-related risk factors include
location of treatment field (e.g., chest wall, head and
neck, facial, skin folds, breast, axilla, perineum), a larger
treatment volume, larger fraction dose (>2.0 Gy per frac-
tion), larger total dose, lower energy photon or electron
used, and the use of bolus material.16e18 Skin areas where
two skin surfaces are in contact (e.g., breast inferior
portion, perineum), where the epidermis is thin and smooth6 7 8 9 10 11
eek
3M
elomet
untreated
ed itchy scores by each application.
Protection against radiation dermatitis 411(e.g., axilla, face, perineum), or where skin integrity has
been disrupted (e.g., surgical wound, lesions, burn) are at
greater risk for a more severe reaction.16
In our study, we had taken into consideration that
symptoms assessed might be subjected to individual sensi-
tivity and tolerance, such as itch and pain, and that
numerous patient-related risk factors mentioned above
would greatly affect the outcome, if each application was
tested on different individuals, as done in many other tri-
als; henceforth, we used intraindividual comparisons (each
patient was given 2 different applications). The short-
coming of our study, however, was the small sample size inFigure 3 Photo of skin reaction on the 46th day (C); Elomet vs. 3
and 3M barrier film (3M) on right side, as shown in diagram on the
0 (A). Reaction is more severe on the 3M barrier film side (C).each group that might affect the significance of the
outcomes.
Two outcomes caught our attention. Firstly, 3M barrier
film may be helpful against radiation induced pruritus. It
was shown in both groups (3M barrier film vs. Elomet and 3M
barrier film vs. untreated) that the skin using 3M barrier film
delayed the appearance of pruritus as compared with Elo-
met and untreated skin. Secondly, corticosteroid may delay
the time to occurrence of grade 2 dermatitis compared with
both untreated skin and 3M barrier film. The difference
reached statistical significance when Elomet was compared
with 3M barrier film.M barrier film where Elomet (E) is applied on left side of photo
right (B); the arrow points to the dotted line of division on day
Figure 4 Photo of skin reaction on the 50th day (C); Elomet vs. untreated where Elomet (E) is applied on left upper of photo and
untreated (U) on right lower as shown in diagram on the right (B); the arrow points to the line of division on day 0 (A). Reaction is
more severe on the untreated side (C).
412 S.-Z. Shaw et al.It has been documented that 3M Cavilon No Sting Barrier
Film can be used in many clinical situations, including
stoma care, protection of skin against body wastes such as
in incontinence, peri-wound protection from exudates
irritation, and protection under adhesive dressing and
tapes.19 Upon application, it forms a long lasting water-
proof barrier on the damaged skin. It acts as a protective
interface between skin and wound fluids, body wastes,
perspiration, adhesive products and friction.20
We hypothesized that, by preventing further water loss
from the skin surface and forming a protection againstfurther irritation, 3M barrier film was able to reduce itching
and delay the occurrence of itching. Our study was
consistent with that of Graham and Schuren. They also
found that with use of 3M barrier film, patients benefited in
terms of reduced pruritus score and increased patient
comfort.9,20
Many studies have confirmed the potent antiinflammatory
effects of topical corticosteroid. Corticosteroid exerts anti-
inflammatory effects through many pathways, including the
inhibition of the release of the enzyme, phospholipase A2,
inhibition of proinflammatory gene transcription factors,
Table 2 Summary and comparison regarding the time to first occurrence of adverse events.
Events Group
3M vs. untreated Elomet vs. untreated Elomet vs. 3M
Time to gr. 1 pruritus D 32.5 vs. D 29.4
p Z 0.079
D 26.4 vs. D 26.8
p Z 0.413
D 28.4 vs. D 32.4
p Z 0.072
Time to pain score 3 D 38.5 vs. D 37.5
p Z 0.618
D 41.5 vs. D 41.2
p Z 0.527
D 45.2 vs. D45.7
p Z 0.451
Time to gr. 2 dermatitis D 44.2 vs. D 46.6
p Z 0.196
D 52 vs. D 43
p Z 0.092
D 53.4 vs. D 44.5
p Z 0.002 (p < 0.05)
Protection against radiation dermatitis 413inhibition of phagocytosis and decrease of the release of
proinflammatory cytokines such as IL-1and IL-6.21,22
Corticosteroid also induces vasoconstriction, decreases
capillary permeability, and inhibits leukocyte proliferation
and migration.23 Janko et al found that mice lacking either
IL-1 or IL-1 receptors, developed less inflammation and less
severe pathological changes in their skins, especially at the
later time points when these mice were put under irradia-
tion,10 linking the IL-1 pathway directly to radiation derma-
titis. Furthermore, Beetz et al reported that corticosteroids
can inhibit the upregulation of IL-6 expression in an irradi-
ated human epithelial cell line.24 Elomet (mometasone
furoate), the corticosteroid cream, has three properties.
Firstly, it is a potent corticosteroid with a low risk of cuta-
neous atrophy, secondly, it has a prolonged effect lasting 24
hours, that is convenient to apply,8 and thirdly, it has been
confirmed that mometasone furoate has an inhibitory effect
on IL-6 activity in the lab.24 Our finding was concordant with
these studies, since Elomet in our study was shown to delay
the time onset of Grade 2 dermatitis by exerting its antiin-
flammatory effect.
Although the incidence of grade 3 dermatitis in the
Elomet application was not statistically superior to the
other two, we found it is the lowest among the three ap-
plications, 15% against 23% and 33%. This result again was
consistent with Elomet, the corticosteroid, having the
antiinflammatory effect, and may be helpful in reducing
radiation dermatitis; however, it was most likely due to our
small sample size that this result could not reach statistical
significance.
In theory, if Elomet is able to reduce the severity of
dermatitis, it should also have an effect on pain and itch
symptoms, but our study did not clearly show this, while
other published studies showed significant findings of
mometasone furoate against pain, itching or other irrita-
tions, compared to placebo.8,25,26 Bearing in mind that
these studies test their materials on two different groups of
individuals, our tentative explanations are that since we
put Elomet and untreated in the same large skin area on the
same individual, perhaps it was difficult to distinguish
which side was less irritated, when the symptom is subtle
and obscure, and perhaps the symptoms may refer to the
other side by nerve pathways.Conclusion
It seems that, with prolonged exposure to radiation,
dermatitis of some degree would eventually occur in timeas a natural process, irrespective of any product used.
Gentle washing with or without pH balanced soap should be
encouraged during the course of treatment. According to
our study results and observations, we also recommend 3M
barrier film to reduce friction and irritation, particularly at
the skin folds and in thin skin areas, such as axilla. It may be
applied from the beginning of radiotherapy. Once the hy-
peremia and pain appear, topical corticosteroid is sug-
gested to reduce inflammation and 3M barrier film may be
discontinued. The effectiveness of corticosteroid on pre-
vention of radiation dermatitis should be further investi-
gated under a larger randomized trial.Acknowledgments
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